Moderna Stock Price, News & Analysis

Moderna (Nasdaq: MRNA) announced its participation in three upcoming virtual investor conferences. The events include the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 1:00 p.m. ET, the Cowen & Co. 41st Annual Health Care Conference on March 1, 2021, at 8:00 a.m. ET, and the Barclays Global Healthcare Conference on March 11, 2021, at 10:20 a.m. ET. Live webcasts will be available on Moderna's investor website and archived for 30 days post-event. Moderna has significantly advanced in mRNA technology, delivering vaccines and therapeutics for various diseases, including COVID-19.

Moderna, Inc. (Nasdaq: MRNA) has supplied 45.4 million doses of its COVID-19 Vaccine to the U.S. Government, with an additional 33.2 million doses in the final production stages. Approximately 25.5 million doses have been administered. Recent short-term delays in production are not expected to impact monthly delivery targets. The company anticipates meeting commitments for all ordered doses, expediting the delivery of the first 300 million doses across various timeframes. Production ramp-up continues, with expected monthly releases of 30-35 million doses for February and March, increasing to 40-50 million by July.

Moderna (Nasdaq: MRNA) has announced a new order commitment from the Canadian Government for an additional 4 million doses of its COVID-19 vaccine, bringing the total to 44 million doses. This increase highlights the Canadian Government's efforts to ensure vaccine availability for its citizens. Moderna's CEO, Stephane Bancel, expressed appreciation for this collaboration and emphasized the confidence in the vaccine's efficacy. Health Canada previously authorized the vaccine for individuals aged 18 and older, demonstrating continued regulatory support for Moderna's mRNA technology.

Moderna (Nasdaq: MRNA) announced the U.S. government's purchase of 100 million additional doses of its COVID-19 vaccine, totaling 300 million confirmed orders. With 41 million doses supplied to date, over 22 million Americans have received the vaccine. Moderna aims to deliver the first 100 million doses by Q1 2021 and the second by Q2 2021, leveraging its U.S. manufacturing capabilities. The company has secured agreements for over 631.5 million doses with various countries, reinforcing its role in the global fight against COVID-19.

Moderna, Inc. (Nasdaq: MRNA) announced that Qatar's Ministry of Public Health granted emergency use authorization for the COVID-19 Vaccine Moderna. This authorization is a significant milestone in the global fight against COVID-19, reflecting confidence in Moderna's mRNA vaccine. The approval is based on scientific evidence from a Phase 3 clinical study. The vaccine has already been authorized in multiple regions, including the U.S., EU, and UK. Moderna remains committed to working with global health agencies to expand its vaccine's availability.

Moderna, Inc. (Nasdaq: MRNA) announced supply agreements for its COVID-19 Vaccine Moderna with Taiwan (5 million doses) and Colombia (10 million doses). Deliveries are set to commence in mid-2021, pending regulatory approvals in both countries. The vaccine is based on mRNA technology and has received various authorizations globally. Moderna emphasizes collaboration with both governments in this effort.

Moderna (Nasdaq: MRNA) will host a live conference call on February 25, 2021, at 8:00 a.m. ET to discuss its fourth quarter and full year 2020 financial results. The call can be accessed by dialing 866-922-5184 domestically or 409-937-8950 internationally, with conference ID 4066945. Moderna has evolved significantly over the past ten years, moving from research-stage activities to commercial success, primarily recognized for its COVID-19 vaccine, now widely used. The company has 24 development programs, with 13 in clinical stages across various therapeutic areas.

Moderna, Inc. (Nasdaq: MRNA) has received interim authorization from the Singapore Health Sciences Authority for its mRNA COVID-19 vaccine under the Pandemic Special Access Route. This decision marks a significant milestone in the global COVID-19 response. The authorization is based on extensive scientific evidence, including data from its pivotal Phase 3 clinical trial. Moderna's vaccine is already approved in several countries, including the U.S., Canada, and the EU. The company continues to advance mRNA technology for various therapeutic areas, supported by strategic alliances with major pharmaceutical firms.

Moderna (Nasdaq: MRNA) announced an increase in its COVID-19 vaccine supply agreement with the Swiss Federal Government from 7.5 million to 13.5 million doses. This decision underscores the government's confidence in Moderna, with deliveries starting in summer 2021 and an option for additional doses in early 2022. The vaccine was authorized by Swissmedic, supporting Moderna's expansion strategy beyond North America. The company continues to enhance its mRNA vaccine platform, which has gained regulatory approval and shows promise in various therapeutic areas.